{"name":"Chiesi Farmaceutici S.p.A.","slug":"chiesi-farmaceutici-spa","ticker":"","exchange":"","domain":"chiesifarmaceuticispa.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":52,"colorKey":"immunology","drugs":[{"name":"Poractant alfa (Curosurf®)","genericName":"Poractant alfa (Curosurf®)","slug":"poractant-alfa-curosurf","indication":"Respiratory distress syndrome (RDS) in premature infants","status":"marketed"},{"name":"Atimos®","genericName":"Atimos®","slug":"atimos","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"marketed"},{"name":"CHF5993 pMDI with HFA-134a","genericName":"CHF5993 pMDI with HFA-134a","slug":"chf5993-pmdi-with-hfa-134a","indication":"Maintenance treatment of asthma","status":"phase_2"},{"name":"Beclomethasone (BDP)","genericName":"Beclomethasone (BDP)","slug":"beclomethasone-bdp","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF 1535 100/6 NEXT DPI® 2 months","genericName":"CHF 1535 100/6 NEXT DPI® 2 months","slug":"chf-1535-100-6-next-dpi-2-months","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF 1535 100/6 µg","genericName":"CHF 1535 100/6 µg","slug":"chf-1535-100-6-g","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF6001 DPI","genericName":"CHF6001 DPI","slug":"chf6001-dpi","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"},{"name":"Fluticasone plus salmeterol fixed combination","genericName":"Fluticasone plus salmeterol fixed combination","slug":"fluticasone-plus-salmeterol-fixed-combination","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Formoterol powder 12 µg/unit dose","genericName":"Formoterol powder 12 µg/unit dose","slug":"formoterol-powder-12-g-unit-dose","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"},{"name":"Foster® NEXThaler® 100/6 µg/unit dose","genericName":"Foster® NEXThaler® 100/6 µg/unit dose","slug":"foster-nexthaler-100-6-g-unit-dose","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Seretide Accuhaler® 500/50 µg/actuation","genericName":"Seretide Accuhaler® 500/50 µg/actuation","slug":"seretide-accuhaler-500-50-g-actuation","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"BDP DPI 2 months","genericName":"BDP DPI 2 months","slug":"bdp-dpi-2-months","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"BDP DPI and formoterol DPI","genericName":"BDP DPI and formoterol DPI","slug":"bdp-dpi-and-formoterol-dpi","indication":"Asthma maintenance therapy","status":"phase_2"},{"name":"BDP HFA 100 µg pMDI","genericName":"BDP HFA 100 µg pMDI","slug":"bdp-hfa-100-g-pmdi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"BDP/FF + Tiotropium","genericName":"BDP/FF + Tiotropium","slug":"bdp-ff-tiotropium","indication":"Asthma (maintenance therapy)","status":"phase_3"},{"name":"BDP/FF/GB","genericName":"BDP/FF/GB","slug":"bdp-ff-gb","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"},{"name":"BDP/Formoterol Next DPI","genericName":"BDP/Formoterol Next DPI","slug":"bdp-formoterol-next-dpi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"BDP/salbutamol CFC pMDI","genericName":"BDP/salbutamol CFC pMDI","slug":"bdp-salbutamol-cfc-pmdi","indication":"Asthma maintenance and reliever therapy","status":"phase_3"},{"name":"BDP/salbutamol HFA pMDI","genericName":"BDP/salbutamol HFA pMDI","slug":"bdp-salbutamol-hfa-pmdi","indication":"Asthma maintenance and reliever therapy","status":"phase_3"},{"name":"Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium","genericName":"Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium","slug":"beclometasone-dipropionate-formoterol-fumarate-glycopyrronium","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"Beclometasone/Formoterol","genericName":"Beclometasone/Formoterol","slug":"beclometasone-formoterol","indication":"Asthma maintenance and reliever therapy","status":"marketed"},{"name":"Beclometasone/Formoterol/Glycopyrrolate","genericName":"Beclometasone/Formoterol/Glycopyrrolate","slug":"beclometasone-formoterol-glycopyrrolate","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"phase_3"},{"name":"Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium","genericName":"Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium","slug":"beclomethasone-dipropionate-formoterol-fumarate-glycopyrronium","indication":"Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults","status":"phase_3"},{"name":"Beclomethasone dipropionate/Salbutamol combination","genericName":"Beclomethasone dipropionate/Salbutamol combination","slug":"beclomethasone-dipropionate-salbutamol-combination","indication":"Asthma maintenance and reliever therapy","status":"phase_3"},{"name":"Beclomethasone plus formoterol fixed combination","genericName":"Beclomethasone plus formoterol fixed combination","slug":"beclomethasone-plus-formoterol-fixed-combination","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Budesonide 200 µg plus formoterol 6 µg DPI","genericName":"Budesonide 200 µg plus formoterol 6 µg DPI","slug":"budesonide-200-g-plus-formoterol-6-g-dpi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Budesonide extrafine pMDI","genericName":"Budesonide extrafine pMDI","slug":"budesonide-extrafine-pmdi","indication":"Maintenance treatment of asthma","status":"phase_2"},{"name":"CHF 1535","genericName":"CHF 1535","slug":"chf-1535","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"CHF 1535 100/6 pMDI 2 months","genericName":"CHF 1535 100/6 pMDI 2 months","slug":"chf-1535-100-6-pmdi-2-months","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF 1535 200/6 µg","genericName":"CHF 1535 200/6 µg","slug":"chf-1535-200-6-g","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF 1535 50/6µg","genericName":"CHF 1535 50/6µg","slug":"chf-1535-50-6-g","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF 4226 pMDI","genericName":"CHF 4226 pMDI","slug":"chf-4226-pmdi","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"phase_2"},{"name":"CHF 5993 100/6/12.5 µg","genericName":"CHF 5993 100/6/12.5 µg","slug":"chf-5993-100-6-12-5-g","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"CHF 5993 200/6/12.5 µg","genericName":"CHF 5993 200/6/12.5 µg","slug":"chf-5993-200-6-12-5-g","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"CHF 5993 DPI","genericName":"CHF 5993 DPI","slug":"chf-5993-dpi","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"},{"name":"CHF 718 pMDI","genericName":"CHF 718 pMDI","slug":"chf-718-pmdi","indication":"Maintenance treatment of asthma","status":"phase_2"},{"name":"CHF1535","genericName":"CHF1535","slug":"chf1535","indication":"Asthma maintenance and reliever therapy","status":"marketed"},{"name":"CHF1535 200/6 µg pMDI","genericName":"CHF1535 200/6 µg pMDI","slug":"chf1535-200-6-g-pmdi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"CHF1535 NEXT DPI","genericName":"CHF1535 NEXT DPI","slug":"chf1535-next-dpi","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"phase_2"},{"name":"CHF1535 NEXThaler","genericName":"CHF1535 NEXThaler","slug":"chf1535-nexthaler","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_2"},{"name":"CHF1535 pMDI","genericName":"CHF1535 pMDI","slug":"chf1535-pmdi","indication":"Maintenance and relief of asthma symptoms","status":"phase_2"},{"name":"CHF5993 pMDI","genericName":"CHF5993 pMDI","slug":"chf5993-pmdi","indication":"Maintenance treatment of asthma","status":"phase_2"},{"name":"Clenil® Modulite® via AeroChamber Plus™","genericName":"Clenil® Modulite® via AeroChamber Plus™","slug":"clenil-modulite-via-aerochamber-plus","indication":"Maintenance and relief of asthma symptoms","status":"phase_2"},{"name":"FlF/VI + Tiotropium","genericName":"FlF/VI + Tiotropium","slug":"flf-vi-tiotropium","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"phase_3"},{"name":"Formoterol 12 µg DPI","genericName":"Formoterol 12 µg DPI","slug":"formoterol-12-g-dpi","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"Formoterol Inhalation Solution","genericName":"Formoterol Inhalation Solution","slug":"formoterol-inhalation-solution","indication":"Chronic obstructive pulmonary disease (COPD)","status":"marketed"},{"name":"Foster BDP/Formoterol","genericName":"Foster BDP/Formoterol","slug":"foster-bdp-formoterol","indication":"Asthma maintenance therapy","status":"marketed"},{"name":"Glycopyrrolate + Formoterol","genericName":"Glycopyrrolate + Formoterol","slug":"glycopyrrolate-formoterol","indication":"Chronic obstructive pulmonary disease (COPD) maintenance therapy","status":"marketed"},{"name":"Seretide® Accuhaler® 250/50 µg/actuation","genericName":"Seretide® Accuhaler® 250/50 µg/actuation","slug":"seretide-accuhaler-250-50-g-actuation","indication":"Asthma maintenance therapy","status":"phase_3"},{"name":"beclomethasone/salbutamol combination","genericName":"beclomethasone/salbutamol combination","slug":"beclomethasone-salbutamol-combination","indication":"Maintenance and relief of asthma symptoms","status":"phase_3"},{"name":"budesonide plus formoterol combination","genericName":"budesonide plus formoterol combination","slug":"budesonide-plus-formoterol-combination","indication":"Maintenance and control of asthma symptoms","status":"phase_3"},{"name":"umeclidinium bromide and vilanterol trifenatate","genericName":"umeclidinium bromide and vilanterol trifenatate","slug":"umeclidinium-bromide-and-vilanterol-trifenatate","indication":"Chronic obstructive pulmonary disease (COPD) maintenance treatment","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":26,"colorKey":"neuroscience","drugs":[{"name":"CHF 5259 12.5 µg","genericName":"CHF 5259 12.5 µg","slug":"chf-5259-12-5-g","indication":"Other","status":"phase_2"},{"name":"CHF5259","genericName":"CHF5259","slug":"chf5259","indication":"Other","status":"phase_1"},{"name":"CHF5259 and CHF6001","genericName":"CHF5259 and CHF6001","slug":"chf5259-and-chf6001","indication":"Other","status":"phase_1"},{"name":"CHF6333","genericName":"CHF6333","slug":"chf6333","indication":"Other","status":"phase_1"},{"name":"CHF718 pMDI with HFA-134a","genericName":"CHF718 pMDI with HFA-134a","slug":"chf718-pmdi-with-hfa-134a","indication":"Other","status":"phase_2"},{"name":"Oleogel-S10","genericName":"Oleogel-S10","slug":"oleogel-s10","indication":"Acute wounds (cuts, abrasions, minor surgical wounds)","status":"phase_3"},{"name":"CH6001","genericName":"CH6001","slug":"ch6001","indication":"Other","status":"phase_1"},{"name":"CHF 1535 Next DPI","genericName":"CHF 1535 Next DPI","slug":"chf-1535-next-dpi","indication":"Cystic fibrosis","status":"phase_2"},{"name":"CHF 1535 pMDI","genericName":"CHF 1535 pMDI","slug":"chf-1535-pmdi","indication":"Other","status":"phase_2"},{"name":"CHF 5188 pMDI","genericName":"CHF 5188 pMDI","slug":"chf-5188-pmdi","indication":"Other","status":"phase_2"},{"name":"CHF 5993 pMDI","genericName":"CHF 5993 pMDI","slug":"chf-5993-pmdi","indication":"Other","status":"phase_1"},{"name":"CHF 6333","genericName":"CHF 6333","slug":"chf-6333","indication":"Other","status":"phase_1"},{"name":"CHF1535 daily dose","genericName":"CHF1535 daily dose","slug":"chf1535-daily-dose","indication":"Other","status":"phase_2"},{"name":"CHF5633","genericName":"CHF5633","slug":"chf5633","indication":"Treatment of cystic fibrosis","status":"phase_2"},{"name":"CHF5993","genericName":"CHF5993","slug":"chf5993","indication":"Other","status":"marketed"},{"name":"CHF6001","genericName":"CHF6001","slug":"chf6001","indication":"Other","status":"phase_2"},{"name":"CHF6366","genericName":"CHF6366","slug":"chf6366","indication":"Other","status":"phase_1"},{"name":"CHF6523","genericName":"CHF6523","slug":"chf6523","indication":"Other","status":"phase_1"},{"name":"Clenil® Modulite® via Volumatic™ spacer","genericName":"Clenil® Modulite® via Volumatic™ spacer","slug":"clenil-modulite-via-volumatic-spacer","indication":"Other","status":"phase_2"},{"name":"Foster","genericName":"Foster","slug":"foster","indication":"Other","status":"marketed"},{"name":"Supra-therapeutic Dose","genericName":"Supra-therapeutic Dose","slug":"supra-therapeutic-dose","indication":"Other","status":"phase_1"},{"name":"Therapeutic Dose 1","genericName":"Therapeutic Dose 1","slug":"therapeutic-dose-1","indication":"Other","status":"phase_1"},{"name":"elapegademase-lvlr","genericName":"elapegademase-lvlr","slug":"elapegademase-lvlr","indication":"Other","status":"marketed"},{"name":"pMDI standard actuator","genericName":"pMDI standard actuator","slug":"pmdi-standard-actuator","indication":"Other","status":"phase_1"},{"name":"tobramycin / Bramitob","genericName":"tobramycin / Bramitob","slug":"tobramycin-bramitob","indication":"Other","status":"phase_3"},{"name":"tobramycin / TOBI","genericName":"tobramycin / TOBI","slug":"tobramycin-tobi","indication":"Other","status":"phase_3"}]},{"name":"Rare Disease","slug":"rare-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ELFABRIO","genericName":"PEGUNIGALSIDASE ALFA-IWXJ","slug":"pegunigalsidase-alfa-iwxj","indication":"Fabry's disease","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"CHF 5259","genericName":"CHF 5259","slug":"chf-5259","indication":"Atrial fibrillation for stroke prevention","status":"phase_2"}]}],"pipeline":[{"name":"ELFABRIO","genericName":"PEGUNIGALSIDASE ALFA-IWXJ","slug":"pegunigalsidase-alfa-iwxj","phase":"marketed","mechanism":"","indications":["Fabry's disease"],"catalyst":""},{"name":"Poractant alfa (Curosurf®)","genericName":"Poractant alfa (Curosurf®)","slug":"poractant-alfa-curosurf","phase":"marketed","mechanism":"Poractant alfa is a natural pulmonary surfactant that reduces surface tension in the lungs and restores normal respiratory function in neonates with respiratory distress syndrome.","indications":["Respiratory distress syndrome (RDS) in premature infants","Meconium aspiration syndrome (MAS) in neonates"],"catalyst":""},{"name":"Atimos®","genericName":"Atimos®","slug":"atimos","phase":"marketed","mechanism":"Atimos is a tiotropium bromide inhalation powder that acts as a long-acting anticholinergic (muscarinic antagonist) to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF5993 pMDI with HFA-134a","genericName":"CHF5993 pMDI with HFA-134a","slug":"chf5993-pmdi-with-hfa-134a","phase":"phase_2","mechanism":"CHF5993 pMDI with HFA-134a is a pressurized metered-dose inhaler formulation of a corticosteroid.","indications":["Maintenance treatment of asthma","Maintenance treatment of COPD"],"catalyst":""},{"name":"Beclomethasone (BDP)","genericName":"Beclomethasone (BDP)","slug":"beclomethasone-bdp","phase":"phase_3","mechanism":"Beclomethasone is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors in the lungs.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF 1535 100/6 NEXT DPI® 2 months","genericName":"CHF 1535 100/6 NEXT DPI® 2 months","slug":"chf-1535-100-6-next-dpi-2-months","phase":"phase_3","mechanism":"CHF 1535 is a fixed-dose combination of beclomethasone dipropionate and formoterol fumarate delivered via a dry powder inhaler for maintenance treatment of asthma and COPD.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 100/6 µg","genericName":"CHF 1535 100/6 µg","slug":"chf-1535-100-6-g","phase":"phase_3","mechanism":"CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 5259","genericName":"CHF 5259","slug":"chf-5259","phase":"phase_2","mechanism":"CHF 5259 is a small molecule drug that acts as a selective inhibitor of the sodium-activated potassium channel, KCNN4.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"CHF 5259 12.5 µg","genericName":"CHF 5259 12.5 µg","slug":"chf-5259-12-5-g","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF5259","genericName":"CHF5259","slug":"chf5259","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF5259 and CHF6001","genericName":"CHF5259 and CHF6001","slug":"chf5259-and-chf6001","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF6001 DPI","genericName":"CHF6001 DPI","slug":"chf6001-dpi","phase":"phase_2","mechanism":"CHF6001 DPI is a dry powder inhaler formulation of a long-acting muscarinic antagonist.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF6333","genericName":"CHF6333","slug":"chf6333","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF718 pMDI with HFA-134a","genericName":"CHF718 pMDI with HFA-134a","slug":"chf718-pmdi-with-hfa-134a","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Fluticasone plus salmeterol fixed combination","genericName":"Fluticasone plus salmeterol fixed combination","slug":"fluticasone-plus-salmeterol-fixed-combination","phase":"phase_3","mechanism":"Fluticasone (a corticosteroid) reduces airway inflammation while salmeterol (a long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Formoterol powder 12 µg/unit dose","genericName":"Formoterol powder 12 µg/unit dose","slug":"formoterol-powder-12-g-unit-dose","phase":"phase_3","mechanism":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle, causing bronchodilation and improved airflow.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma (maintenance therapy)"],"catalyst":""},{"name":"Foster® NEXThaler® 100/6 µg/unit dose","genericName":"Foster® NEXThaler® 100/6 µg/unit dose","slug":"foster-nexthaler-100-6-g-unit-dose","phase":"phase_3","mechanism":"Foster NEXThaler combines beclomethasone dipropionate (an inhaled corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in asthma and COPD.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Oleogel-S10","genericName":"Oleogel-S10","slug":"oleogel-s10","phase":"phase_3","mechanism":"Oleogel-S10 is a topical oleogel formulation containing birch bark extract that promotes wound healing and tissue repair through anti-inflammatory and antimicrobial properties.","indications":["Acute wounds (cuts, abrasions, minor surgical wounds)","Chronic wounds and ulcers"],"catalyst":""},{"name":"Seretide Accuhaler® 500/50 µg/actuation","genericName":"Seretide Accuhaler® 500/50 µg/actuation","slug":"seretide-accuhaler-500-50-g-actuation","phase":"phase_3","mechanism":"Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"BDP DPI 2 months","genericName":"BDP DPI 2 months","slug":"bdp-dpi-2-months","phase":"phase_3","mechanism":"BDP (beclomethasone dipropionate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"BDP DPI and formoterol DPI","genericName":"BDP DPI and formoterol DPI","slug":"bdp-dpi-and-formoterol-dpi","phase":"phase_2","mechanism":"This combination inhaler delivers beclomethasone dipropionate (a corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and improve bronchial smooth muscle relaxation in obstructive airway diseases.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"BDP HFA 100 µg pMDI","genericName":"BDP HFA 100 µg pMDI","slug":"bdp-hfa-100-g-pmdi","phase":"phase_3","mechanism":"BDP (beclomethasone dipropionate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in the lungs.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"BDP/FF + Tiotropium","genericName":"BDP/FF + Tiotropium","slug":"bdp-ff-tiotropium","phase":"phase_3","mechanism":"BDP/FF (beclomethasone/formoterol) is an inhaled corticosteroid plus long-acting beta-2 agonist combination that reduces airway inflammation and bronchospasm, while tiotropium is a long-acting muscarinic antagonist that provides sustained bronchodilation.","indications":["Asthma (maintenance therapy)","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"BDP/FF/GB","genericName":"BDP/FF/GB","slug":"bdp-ff-gb","phase":"phase_3","mechanism":"BDP/FF/GB is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation through multiple pathways.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma (potential indication under investigation)"],"catalyst":""},{"name":"BDP/Formoterol Next DPI","genericName":"BDP/Formoterol Next DPI","slug":"bdp-formoterol-next-dpi","phase":"phase_3","mechanism":"BDP/Formoterol combines an inhaled corticosteroid (beclomethasone dipropionate) with a long-acting beta-2 agonist (formoterol) to reduce airway inflammation and improve bronchial smooth muscle relaxation.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"BDP/salbutamol CFC pMDI","genericName":"BDP/salbutamol CFC pMDI","slug":"bdp-salbutamol-cfc-pmdi","phase":"phase_3","mechanism":"BDP/salbutamol is a combination inhaler that reduces airway inflammation via corticosteroid action while providing rapid bronchodilation through beta-2 agonist stimulation.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction"],"catalyst":""},{"name":"BDP/salbutamol HFA pMDI","genericName":"BDP/salbutamol HFA pMDI","slug":"bdp-salbutamol-hfa-pmdi","phase":"phase_3","mechanism":"BDP/salbutamol is a combination inhaler that reduces airway inflammation via corticosteroid action while providing rapid bronchodilation through beta-2 agonist stimulation.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction"],"catalyst":""},{"name":"Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium","genericName":"Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium","slug":"beclometasone-dipropionate-formoterol-fumarate-glycopyrronium","phase":"phase_3","mechanism":"This triple-combination inhaler delivers a corticosteroid to reduce airway inflammation, a long-acting beta-2 agonist to relax airway smooth muscle, and an anticholinergic to further dilate airways.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy","Asthma maintenance therapy (in select populations)"],"catalyst":""},{"name":"Beclometasone/Formoterol","genericName":"Beclometasone/Formoterol","slug":"beclometasone-formoterol","phase":"marketed","mechanism":"Beclometasone is a corticosteroid that reduces airway inflammation, while formoterol is a long-acting beta-2 agonist that relaxes bronchial smooth muscle, together providing anti-inflammatory and bronchodilatory effects.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Beclometasone/Formoterol/Glycopyrrolate","genericName":"Beclometasone/Formoterol/Glycopyrrolate","slug":"beclometasone-formoterol-glycopyrrolate","phase":"phase_3","mechanism":"This triple-combination inhaler delivers a corticosteroid (beclometasone) to reduce airway inflammation, a long-acting beta-2 agonist (formoterol) to dilate airways, and an anticholinergic (glycopyrrolate) to further relax airway smooth muscle.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium","genericName":"Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium","slug":"beclomethasone-dipropionate-formoterol-fumarate-glycopyrronium","phase":"phase_3","mechanism":"This triple-combination inhaler delivers a corticosteroid to reduce airway inflammation, a long-acting beta-2 agonist to relax airway smooth muscle, and an anticholinergic to further dilate airways.","indications":["Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults"],"catalyst":""},{"name":"Beclomethasone dipropionate/Salbutamol combination","genericName":"Beclomethasone dipropionate/Salbutamol combination","slug":"beclomethasone-dipropionate-salbutamol-combination","phase":"phase_3","mechanism":"This combination inhaler delivers a corticosteroid to reduce airway inflammation and a short-acting beta-2 agonist to rapidly relax bronchial smooth muscle.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Beclomethasone plus formoterol fixed combination","genericName":"Beclomethasone plus formoterol fixed combination","slug":"beclomethasone-plus-formoterol-fixed-combination","phase":"phase_3","mechanism":"Beclomethasone (a corticosteroid) reduces airway inflammation while formoterol (a long-acting beta-2 agonist) relaxes airway smooth muscle to improve breathing.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Budesonide 200 µg plus formoterol 6 µg DPI","genericName":"Budesonide 200 µg plus formoterol 6 µg DPI","slug":"budesonide-200-g-plus-formoterol-6-g-dpi","phase":"phase_3","mechanism":"Budesonide reduces airway inflammation while formoterol relaxes airway smooth muscle, together improving airflow and reducing asthma/COPD symptoms.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Budesonide extrafine pMDI","genericName":"Budesonide extrafine pMDI","slug":"budesonide-extrafine-pmdi","phase":"phase_2","mechanism":"Budesonide extrafine pMDI is a corticosteroid that works by reducing inflammation in the lungs.","indications":["Maintenance treatment of asthma","Maintenance treatment of COPD"],"catalyst":""},{"name":"CH6001","genericName":"CH6001","slug":"ch6001","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF 1535","genericName":"CHF 1535","slug":"chf-1535","phase":"phase_3","mechanism":"CHF 1535 is a dual bronchodilator that combines a long-acting beta-2 agonist with a long-acting muscarinic antagonist to improve airway function in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 100/6 pMDI 2 months","genericName":"CHF 1535 100/6 pMDI 2 months","slug":"chf-1535-100-6-pmdi-2-months","phase":"phase_3","mechanism":"CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 200/6 µg","genericName":"CHF 1535 200/6 µg","slug":"chf-1535-200-6-g","phase":"phase_3","mechanism":"CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 50/6µg","genericName":"CHF 1535 50/6µg","slug":"chf-1535-50-6-g","phase":"phase_3","mechanism":"CHF 1535 is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist that reduces airway inflammation and improves bronchodilation in respiratory disease.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 1535 Next DPI","genericName":"CHF 1535 Next DPI","slug":"chf-1535-next-dpi","phase":"phase_2","mechanism":"CHF 1535 Next DPI is a dry powder inhaler for the treatment of cystic fibrosis.","indications":["Cystic fibrosis"],"catalyst":""},{"name":"CHF 1535 pMDI","genericName":"CHF 1535 pMDI","slug":"chf-1535-pmdi","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF 4226 pMDI","genericName":"CHF 4226 pMDI","slug":"chf-4226-pmdi","phase":"phase_2","mechanism":"CHF 4226 is an inhaled dual bronchodilator combining a long-acting beta-2 agonist and long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"CHF 5188 pMDI","genericName":"CHF 5188 pMDI","slug":"chf-5188-pmdi","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF 5993 100/6/12.5 µg","genericName":"CHF 5993 100/6/12.5 µg","slug":"chf-5993-100-6-12-5-g","phase":"phase_3","mechanism":"CHF 5993 is a triple-combination inhaled corticosteroid/long-acting beta-2 agonist/long-acting muscarinic antagonist that reduces airway inflammation and improves bronchodilation through multiple pathways.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy","Asthma maintenance therapy (potential)"],"catalyst":""},{"name":"CHF 5993 200/6/12.5 µg","genericName":"CHF 5993 200/6/12.5 µg","slug":"chf-5993-200-6-12-5-g","phase":"phase_3","mechanism":"CHF 5993 is a triple-combination inhaled therapy that combines a long-acting beta-2 agonist, long-acting muscarinic antagonist, and inhaled corticosteroid to improve airway function and reduce inflammation in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"CHF 5993 DPI","genericName":"CHF 5993 DPI","slug":"chf-5993-dpi","phase":"phase_2","mechanism":"CHF 5993 DPI is a dry powder inhaler formulation of a specific drug.","indications":["Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF 5993 pMDI","genericName":"CHF 5993 pMDI","slug":"chf-5993-pmdi","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF 6333","genericName":"CHF 6333","slug":"chf-6333","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF 718 pMDI","genericName":"CHF 718 pMDI","slug":"chf-718-pmdi","phase":"phase_2","mechanism":"CHF 718 pMDI is a corticosteroid used to reduce inflammation in the airways.","indications":["Maintenance treatment of asthma","Treatment of chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF1535","genericName":"CHF1535","slug":"chf1535","phase":"marketed","mechanism":"CHF1535 is a fixed-dose combination of beclomethasone dipropionate and formoterol fumarate that reduces airway inflammation and provides bronchodilation for respiratory disease management.","indications":["Asthma maintenance and reliever therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF1535 200/6 µg pMDI","genericName":"CHF1535 200/6 µg pMDI","slug":"chf1535-200-6-g-pmdi","phase":"phase_3","mechanism":"CHF1535 is a fixed-dose combination of beclomethasone dipropionate (ICS) and formoterol (LABA) that reduces airway inflammation and improves bronchial smooth muscle relaxation.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF1535 NEXT DPI","genericName":"CHF1535 NEXT DPI","slug":"chf1535-next-dpi","phase":"phase_2","mechanism":"CHF1535 is a dual bronchodilator combining an inhaled corticosteroid with a long-acting beta-2 agonist and long-acting muscarinic antagonist for maintenance treatment of chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""},{"name":"CHF1535 NEXThaler","genericName":"CHF1535 NEXThaler","slug":"chf1535-nexthaler","phase":"phase_2","mechanism":"CHF1535 NEXThaler is a dry powder inhaler delivering a fixed dose of a combination of fluticasone furoate and umeclidinium","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma"],"catalyst":""},{"name":"CHF1535 daily dose","genericName":"CHF1535 daily dose","slug":"chf1535-daily-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF1535 pMDI","genericName":"CHF1535 pMDI","slug":"chf1535-pmdi","phase":"phase_2","mechanism":"CHF1535 pMDI is a corticosteroid inhalation powder.","indications":["Maintenance and relief of asthma symptoms","Maintenance treatment of COPD symptoms"],"catalyst":""},{"name":"CHF5633","genericName":"CHF5633","slug":"chf5633","phase":"phase_2","mechanism":"CHF5633 is a small molecule in development for the treatment of cystic fibrosis.","indications":["Treatment of cystic fibrosis"],"catalyst":""},{"name":"CHF5993","genericName":"CHF5993","slug":"chf5993","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF5993 pMDI","genericName":"CHF5993 pMDI","slug":"chf5993-pmdi","phase":"phase_2","mechanism":"CHF5993 pMDI is a corticosteroid inhalation powder for the maintenance treatment of asthma and the treatment of chronic obstructive pulmonary disease (COPD).","indications":["Maintenance treatment of asthma","Treatment of chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"CHF6001","genericName":"CHF6001","slug":"chf6001","phase":"phase_2","mechanism":"CHF6001 is a phosphodiesterase 4 (PDE4) inhibitor that reduces inflammation in the airways.","indications":[],"catalyst":""},{"name":"CHF6366","genericName":"CHF6366","slug":"chf6366","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CHF6523","genericName":"CHF6523","slug":"chf6523","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Clenil® Modulite® via AeroChamber Plus™","genericName":"Clenil® Modulite® via AeroChamber Plus™","slug":"clenil-modulite-via-aerochamber-plus","phase":"phase_2","mechanism":"Clenil Modulite is a corticosteroid that reduces inflammation in the airways.","indications":["Maintenance and relief of asthma symptoms","Maintenance treatment of chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"Clenil® Modulite® via Volumatic™ spacer","genericName":"Clenil® Modulite® via Volumatic™ spacer","slug":"clenil-modulite-via-volumatic-spacer","phase":"phase_2","mechanism":"Beclometasone dipropionate is a synthetic corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors.","indications":[],"catalyst":""},{"name":"FlF/VI + Tiotropium","genericName":"FlF/VI + Tiotropium","slug":"flf-vi-tiotropium","phase":"phase_3","mechanism":"FlF/VI is a fixed-dose combination of fluticasone furoate and vilanterol (long-acting beta-2 agonist and inhaled corticosteroid) combined with tiotropium (long-acting muscarinic antagonist) to provide multi-mechanism bronchodilation and anti-inflammatory effects in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Formoterol 12 µg DPI","genericName":"Formoterol 12 µg DPI","slug":"formoterol-12-g-dpi","phase":"phase_3","mechanism":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Formoterol Inhalation Solution","genericName":"Formoterol Inhalation Solution","slug":"formoterol-inhalation-solution","phase":"marketed","mechanism":"Formoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma (maintenance therapy)"],"catalyst":""},{"name":"Foster","genericName":"Foster","slug":"foster","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Foster BDP/Formoterol","genericName":"Foster BDP/Formoterol","slug":"foster-bdp-formoterol","phase":"marketed","mechanism":"Foster combines beclomethasone dipropionate (a corticosteroid) and formoterol (a long-acting beta-2 agonist) to reduce airway inflammation and dilate airways in asthma and COPD.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Glycopyrrolate + Formoterol","genericName":"Glycopyrrolate + Formoterol","slug":"glycopyrrolate-formoterol","phase":"marketed","mechanism":"Glycopyrrolate is an anticholinergic agent that blocks muscarinic receptors to reduce airway secretions and bronchoconstriction, while formoterol is a long-acting beta-2 agonist that relaxes airway smooth muscle.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Seretide® Accuhaler® 250/50 µg/actuation","genericName":"Seretide® Accuhaler® 250/50 µg/actuation","slug":"seretide-accuhaler-250-50-g-actuation","phase":"phase_3","mechanism":"Seretide combines a long-acting beta-2 agonist (salmeterol) and an inhaled corticosteroid (fluticasone propionate) to relax airway smooth muscle and reduce airway inflammation.","indications":["Asthma maintenance therapy","Chronic obstructive pulmonary disease (COPD) maintenance therapy"],"catalyst":""},{"name":"Supra-therapeutic Dose","genericName":"Supra-therapeutic Dose","slug":"supra-therapeutic-dose","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Therapeutic Dose 1","genericName":"Therapeutic Dose 1","slug":"therapeutic-dose-1","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"beclomethasone/salbutamol combination","genericName":"beclomethasone/salbutamol combination","slug":"beclomethasone-salbutamol-combination","phase":"phase_3","mechanism":"Beclomethasone is a corticosteroid that reduces inflammation, while salbutamol is a beta-2 adrenergic receptor agonist that relaxes airway smooth muscle.","indications":["Maintenance and relief of asthma symptoms","Maintenance and relief of chronic obstructive pulmonary disease (COPD) symptoms"],"catalyst":""},{"name":"budesonide plus formoterol combination","genericName":"budesonide plus formoterol combination","slug":"budesonide-plus-formoterol-combination","phase":"phase_3","mechanism":"Budesonide is a corticosteroid that reduces inflammation, while formoterol is a long-acting beta2-adrenergic receptor agonist that relaxes airway muscles.","indications":["Maintenance and control of asthma symptoms","Chronic obstructive pulmonary disease (COPD)"],"catalyst":""},{"name":"elapegademase-lvlr","genericName":"elapegademase-lvlr","slug":"elapegademase-lvlr","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"pMDI standard actuator","genericName":"pMDI standard actuator","slug":"pmdi-standard-actuator","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"tobramycin / Bramitob","genericName":"tobramycin / Bramitob","slug":"tobramycin-bramitob","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"tobramycin / TOBI","genericName":"tobramycin / TOBI","slug":"tobramycin-tobi","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"umeclidinium bromide and vilanterol trifenatate","genericName":"umeclidinium bromide and vilanterol trifenatate","slug":"umeclidinium-bromide-and-vilanterol-trifenatate","phase":"marketed","mechanism":"Umeclidinium is a long-acting muscarinic antagonist and vilanterol is a long-acting beta-2 agonist that together relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.","indications":["Chronic obstructive pulmonary disease (COPD) maintenance treatment"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":80,"phaseCounts":{"marketed":12,"phase_2":22,"phase_3":35,"phase_1":11},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}